Abstract: Techniques to detect for end of service using dynamic inactivity timer thresholds are described. An access terminal establishes a radio connection for one or more applications. Data and signaling for the application(s) may be sent on one or more first flows (e.g., RLP flows) that may carry any number of second flows (e.g., IP flows). The access terminal determines a dynamic inactivity timer threshold for each first flow, e.g., based on at least one inactivity timer threshold for at least one second flow mapped to that first flow. The access terminal determines whether each first flow is inactive based on the inactivity timer threshold for that first flow, e.g., declares each first flow to be inactive if no activity is detected on that first flow for a period exceeding the inactivity timer threshold. The access terminal closes the radio connection when all first flow(s) are determined to be inactive.

Abstract: The present invention relates to regulation of antigen presentation by cytokine signaling regulators in antigen presenting cells, such as dendritic cells. The invention provides methods of modulating antigen presentation through modulation of cytokine signaling regulators, such as SOCS (SOCS1-7, CIS), SHP (SHP-1 and SHP-2) or PIAS (PIAS1, PIAS3, PIASx and PIASy). The present invention provides vaccines and therapies in which antigen presentation is enhanced through modulation of cytokine signaling regulators. The present invention also provides a mechanism to break self tolerance in tumor vaccination methods that rely on presentation of self tumor antigens.

Abstract: A method and computer program product for testing using asynchronous automated virtual agent behavior is presented. A communication including one of a web-based communication and a telephony-based communication is received at a contact center. The communication is responded to by a virtual agent simulating actions of an agent in a coordinated, asynchronous manner. The virtual agent is capable of providing a response to the web-based communication and to the telephony-based communication. At least one parameter of said contact center is measured and the results are presented to a contact center manager.

Abstract: A method, apparatus and computer program product for generating a test script for use by a test agent is presented. A first test script is generated in a first language. A determination is then made whether to generate an intermediate test script from the first test script. When the determination is made not to generate an intermediate test script then the first test script is converted into a second test script in a second language, and the first test script is also converted into a callback test script. When the determination is made to generate an intermediate test script then an intermediate test script is generated from the first test script. The intermediate test script is converted into a second test script in a second language, and the intermediate test script is converted into a callback test script. The second test script and the callback test script are compiled into a final test script.

Abstract: To mitigate re-syncs, RLP sync control frames associated with a packet data session can be sequence numbered. A single sequence number can be assigned for an entire sync procedure associated with the initiation of a packet data session. For example, the sequence number can remains the same on all sync control frames (SYNC, SYNC/ACK, ACK) of a particular packet data session. When a sync frame is received out of order within a single sequence, it can be ignored under certain conditions. For example, if a SYNC frame with a sequence number 0 is received out of order after an ACK frame with sequence number 0 is received, the mobile station can ignore the out of order SYNC frame. Thus, an RLP re-sync is avoided due to out of order RLP sync packets.

Abstract: Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

Abstract: Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.